Clinical characteristics and prognosis of MLL-AF6 positive patients with acute myeloid leukemia.
- Author:
Mei Xiang ZHANG
1
;
Wen Zhi SHI
2
;
Jian Xin LIU
1
;
Chun Jian WANG
1
;
Yan LI
1
;
Wei WANG
1
;
Bin JIANG
1
Author Information
1. Department of Hematology, Peking University International Hospital, Beijing 102206, China.
2. Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, Shanxi, China.
- Publication Type:Journal Article
- Keywords:
Disease attributes;
Gene fusion;
Gene rearrangement;
Leukemia, myeloid;
MLL-AF6;
Prognosis
- MeSH:
Adult;
Female;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid, Acute/genetics*;
Male;
Myeloid-Lymphoid Leukemia Protein/genetics*;
Oncogene Proteins, Fusion/genetics*;
Prognosis;
Remission Induction;
Retrospective Studies
- From:
Journal of Peking University(Health Sciences)
2021;53(5):915-920
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical features and prognosis of acute myeloid leukemia (AML) patients with the mixed lineage leukemia (MLL) gene rearrangements AF6 (MLL-AF6) positive.
METHODS:In the study, 11 patients who were newly diagnosed with MLL-AF6 positive AML were analyzed retrospectively, related literature was reviewed to clarify the clinical features and prognosis of MLL-AF6 positive patients.
RESULTS:Among the 11 patients, there were 6 males and 5 females, with a median age of 36 years. Six patients were diagnosed with AML M5 and five with M4 according to FAB classification (French-American-British classification systems). Gingival swelling and pain occurred in 6 cases and fever occurred in 5 cases. At first diagnosis, the median white blood cells were 55.5×109/L. Immunotype showed the expression of myeloid/monocyte and early stem cell series antigens. The expression level of MLL-AF6 fusion gene (real-time quantitative PCR) was 14.2%-214.5%, and 6/11 cases (54.5%) were associated with high EVI1 gene expression. Mutations of KRAS, TET2, ASXL1, TP53, DNMT3A, and FLT3-ITD were detected by next generation sequencing (NGS) in 4 patients. Chromosome G banding examination showed that 2 cases were t(6;11)(q27, q23) with complex karyotype abnormality, 4 cases with +8 abnormality and 2 cases with normal karyotype. Hematological complete remission (CR) was achieved in 8/11 patients (72.7%) after conventional induction chemotherapy, and primary drug resistance was observed in 3 patients. Two of the eight patients with CR were negative for minimal residual disease (MRD), with a median CR duration of 4.5 months. Two patients with positive MRD and three patients with refractory recurrence underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), but all died due to leukemia progression. At the end of follow-up on December 1, 2019, 2 patients were alive and 9 died, with median survival time of 9 months.
CONCLUSION:The AML patients with MLL-AF6 positive were mostly young, the majority of FAB types were M4 and M5, and most of the patients often had fever as the first symptom, with increased white blood cells, accompanied by organ infiltration, and high EVI1 gene expression. The hematological remission rate of routine chemotherapy is not low, but it is difficult to achieve molecular remission, most of which have early recurrence. Early allo-HSCT in a molecular negative state may prolong the CR duration.
